

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	VELAGLUCERASE ALFA
PRONUNCIATION	vel" a gloo' ser ase
THERAPEUTIC CLAIM	Treatment of patients with Gaucher disease

CHEMICAL NAMES

1. Ceramidase, glucosyl-(human HT-1080 cell)
2. Human glucosylceramidase (EC 3.2.1.45 or Beta-glucocerebrosidase), glycoform α

STRUCTURAL FORMULA

ARPCIPKSFQ	YSSVVCVCNA	TYCDSFDPPT	FPALGTFSRY	ESTRSGRRME	50
LSMGPIQANH	TGTGLLLTLQ	PEQKFQKVKG	FGGAMTDAAA	LNILALSPPA	100
QNLLLSYFSS	EEGIGYNIIR	VPMASCDFSI	RTYTYADTPD	DFQLHNFSLP	150
EEDTKLKIPL	IHRALQLAQR	PVSLLASPWT	SPTWLKTNGA	VNGKGSCLKGQ	200
PGDIYHQTWA	RYFVKFLDAY	AEHKLQFWAV	TAENEPSAGL	LSGYPFQCLG	250
FTPEHQRFDI	ARDLGPTLAN	STHHNVRLLM	LDDQRLLLP	WAKVVLTDPE	300
AAKYVHGIIV	HWYLDLFLAPA	KATLGETHRL	FPNTMLFASE	ACVGSKFWEQ	350
SVRLGSWDRG	MQYSHSIITN	LLYHVVGWTD	WNLALNPEGG	PNWVRNFVDS	400
PIIVDITKDT	FYKQPMFYHL	GHFSKFIPEG	SQRVGLVASQ	KNDLDAVALM	450
HPDGSAVVVV	LNRSSKDVPL	TIKDPAVGFL	ETISPGYSIH	TYLWRRQ	497

Glycosylation sites

Asn-19 Asn-59 Asn-146 Asn-270 Asn-462

MOLECULAR FORMULA	$C_{2532}H_{3854}N_{672}O_{711}S_{16}$
MOLECULAR WEIGHT	55.6 kDa (protein)
CODE	EC 3.2.1.45
TRADEMARK	None
MANUFACTURER	Shire Human Genetic Therapies, Inc.
<u>CAS</u> REGISTRY NUMBER	884604-91-5